CBFA2T3

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Core-binding factor, runt domain, alpha subunit 2; translocated to, 3
Protein CBFA2T3 PDB 2h7b.png
PDB rendering based on 2h7b.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols CBFA2T3 ; ETO2; MTG16; MTGR2; ZMYND4
External IDs OMIM603870 MGI1338013 HomoloGene74543 GeneCards: CBFA2T3 Gene
RNA expression pattern
PBB GE CBFA2T3 208056 s at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 863 12398
Ensembl ENSG00000129993 ENSMUSG00000006362
UniProt O75081 O54972
RefSeq (mRNA) NM_005187 NM_001109873
RefSeq (protein) NP_005178 NP_001103343
Location (UCSC) Chr 16:
88.94 – 89.04 Mb
Chr 8:
122.63 – 122.7 Mb
PubMed search [1] [2]

Protein CBFA2T3 is a protein that in humans is encoded by the CBFA2T3 gene.[1][2]

Function[edit]

The t(16;21)(q24;q22) translocation is a rare but recurrent chromosomal abnormality associated with therapy-related myeloid malignancies. The translocation produces a chimeric gene made up of the 5'-region of the AML1 gene fused to the 3'-region of this gene. In addition, this gene is a putative breast tumor suppressor. Two transcript variants encoding different isoforms have been found for this gene, and a brefeldin A-sensitive association of RII-alpha protein with one of the isoforms has been demonstrated in the Golgi apparatus.[2]

Interactions[edit]

CBFA2T3 has been shown to interact with:

References[edit]

  1. ^ Calabi F, Cilli V (Dec 1998). "CBFA2T1, a gene rearranged in human leukemia, is a member of a multigene family". Genomics 52 (3): 332–41. doi:10.1006/geno.1998.5429. PMID 9790752. 
  2. ^ a b "Entrez Gene: CBFA2T3 core-binding factor, runt domain, alpha subunit 2; translocated to, 3". 
  3. ^ a b c Hoogeveen A, Rossetti S, Stoyanova V, Schonkeren J, Fenaroli A, Schiaffonati L et al. (Sep 2002). "The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies". Oncogene 21 (43): 6703–12. doi:10.1038/sj.onc.1205882. PMID 12242670. 
  4. ^ a b Amann J, Nip J, Strom D, Lutterbach B, Harada H, Lenny N et al. (Oct 2001). "ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain". Mol. Cell. Biol. 21 (19): 6470–83. PMC 99794. PMID 11533236. 
  5. ^ a b c Goardon N, Lambert J, Rodriguez P, Nissaire P, Herblot S, Thibault P et al. (Jan 2006). "ETO2 coordinates cellular proliferation and differentiation during erythropoiesis". EMBO J. 25 (2): 357–66. doi:10.1038/sj.emboj.7600934. PMC 1383517. PMID 16407974. 
  6. ^ Schillace R, Andrews S, Liberty G, Davey M, Carr D (Feb 2002). "Identification and characterization of myeloid translocation gene 16b as a novel a kinase anchoring protein in T lymphocytes". J. Immunol. 168 (4): 1590–9. PMID 11823486. 
  7. ^ Lindberg S, Olsson A, Persson A, Olsson I (Dec 2003). "Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins". Eur. J. Haematol. 71 (6): 439–47. PMID 14703694. 

Further reading[edit]

  • Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K et al. (1998). "The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1.". Mol. Cell. Biol. 18 (2): 846–58. PMC 108796. PMID 9447981. 
  • Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y et al. (1998). "The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family.". Blood 91 (11): 4028–37. PMID 9596646. 
  • Schillace R, Andrews S, Liberty G, Davey M, Carr D (2002). "Identification and characterization of myeloid translocation gene 16b as a novel a kinase anchoring protein in T lymphocytes.". J. Immunol. 168 (4): 1590–9. doi:10.4049/jimmunol.168.4.1590. PMID 11823486. 
  • Kondoh K, Nakata Y, Furuta T, Hosoda F, Gamou T, Kurosawa Y et al. (2003). "A pediatric case of secondary leukemia associated with t(16;21)(q24;q22) exhibiting the chimeric AML1-MTG16 gene.". Leuk. Lymphoma 43 (2): 415–20. doi:10.1080/10428190290006242. PMID 11999578. 
  • Kochetkova M, McKenzie O, Bais A, Martin J, Secker G, Seshadri R et al. (2002). "CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3.". Cancer Res. 62 (16): 4599–604. PMID 12183414. 
  • Powell J, Gardner A, Bais A, Hinze S, Baker E, Whitmore S et al. (2003). "Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes.". Genomics 80 (3): 303–10. doi:10.1006/geno.2002.6828. PMID 12213200. 
  • Hoogeveen A, Rossetti S, Stoyanova V, Schonkeren J, Fenaroli A, Schiaffonati L et al. (2002). "The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies.". Oncogene 21 (43): 6703–12. doi:10.1038/sj.onc.1205882. PMID 12242670. 
  • Lindberg S, Olsson A, Persson A, Olsson I (2004). "Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins.". Eur. J. Haematol. 71 (6): 439–47. doi:10.1046/j.0902-4441.2003.00166.x. PMID 14703694. 
  • Ibañez V, Sharma A, Buonamici S, Verma A, Kalakonda S, Wang J et al. (2004). "AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.". Cancer Res. 64 (13): 4547–54. doi:10.1158/0008-5472.CAN-03-3689. PMID 15231665. 
  • Kumar R, Manning J, Spendlove H, Kremmidiotis G, McKirdy R, Lee J et al. (2006). "ZNF652, a novel zinc finger protein, interacts with the putative breast tumor suppressor CBFA2T3 to repress transcription.". Mol. Cancer Res. 4 (9): 655–65. doi:10.1158/1541-7786.MCR-05-0249. PMID 16966434. 

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.